PolyPid Ltd., a clinical-stage pharmaceutical company, develops, manufactures, and commercializes products based on polymer-lipid encapsulation matrix (PLEX) platform to address unmet medical needs. Its lead product candidate is D-PLEX100, which helps in the prevention of sternal (bone) surgical site infections (SSIs), as well as for the prevention of abdominal (soft tissue) SSIs. It is also developing OncoPLEX, for the treatment of intra-tumoral cancer. PolyPid Ltd. was incorporated in 2008 and is headquartered in Petah Tikva, Israel.
Stock data | 2024 | Change |
---|---|---|
Price | $3.22 | N/A |
Market Cap | $5.32M | N/A |
Shares Outstanding | 1.65M | N/A |
Employees | 57.00 | N/A |